Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
公司代碼TIVC
公司名稱Tivic Health Systems Inc
上市日期Nov 11, 2021
CEOErnst (Jennifer)
員工數量7
證券類型Ordinary Share
年結日Nov 11
公司地址47685 Lakeview Blvd
城市FREMONT
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94538
電話18882766888
網址https://tivichealth.com/
公司代碼TIVC
上市日期Nov 11, 2021
CEOErnst (Jennifer)